Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma.
10.3760/cma.j.cn112139-20220729-00328
- Collective Name:Rare Kidney Cancer Collaborative Group, Genitourinary Cancer Committee, China Anti-Cancer Association
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Renal Cell/therapy*;
Fumarate Hydratase/genetics*;
Consensus;
Kidney Neoplasms/therapy*;
Immunohistochemistry
- From:
Chinese Journal of Surgery
2022;60(11):961-968
- CountryChina
- Language:Chinese
-
Abstract:
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is an independent pathological subtype of renal cell carcinoma with a clear driver gene and a high degree of malignancy. Recent studies have found that patients with somatic FH mutations have similar clinico-biological behavior and poor prognosis to patients with germline FH mutations. FH-RCC has the characteristics of early age of onset, atypical imaging manifestations, variable pathological patterns, difficult clinical diagnosis and poor effect on traditional drug treatment, thus greatly endangering the life and health of patients. Under the organization of the Rare Kidney Cancer Collaborative Group, Genitourinary Cancer Committee, China Anti-Cancer Association, this guideline was developed based on basic research, clinical cohort and evidence-based medicine evidence, including imaging manifestations, pathological diagnosis, genetic testing, surgical and systemic treatment options, and provided recommendations and references for the diagnosis and treatment norms.
